COVID-19 vaccines do not increase the risk of thrombosis in patients with MPN; as the humoral response of patients with myeloid malig- nancies to the mRNA-based vaccines appears to be satisfactory it is pivotal to vaccinate the highest number of patients with MPN, reassuring them regarding vascular complications.
SARS-CoV-2 vaccination and thrombotic risk in myeloproliferative neoplasms
Borsani O;Casetti IC;Vanni D;Arcaini L;Rumi E.
2023-01-01
Abstract
COVID-19 vaccines do not increase the risk of thrombosis in patients with MPN; as the humoral response of patients with myeloid malig- nancies to the mRNA-based vaccines appears to be satisfactory it is pivotal to vaccinate the highest number of patients with MPN, reassuring them regarding vascular complications.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
